Potential of NOTCH1 Mutation to Predict Anti-PD1 Treatment Outcomes in Patients with Oesophageal Squamous Cell Cancer By Ogkologos - April 23, 2025 802 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from a biomarker analysis from the RATIONALE-302 study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Belzutifan with Pembrolizumab for Adjuvant Treatment of Renal Cell Carcinoma How Decades of NCI Support Led to Groundbreaking Discoveries: The Story of Immune Checkpoint Inhibitors Adding Belzutifan to Pembrolizumab Prolongs DFS After Nephrectomy in Patients with ccRCC at Increased Risk for Recurrence MOST POPULAR COVID-19: “We’ve got so much on our plates” August 4, 2020 FDA Oversight of E-Cigarettes Gathers Speed: A Conversation with Mitch Zeller January 5, 2022 Trastuzumab Deruxtecan Shows Promising Activity Among Patients with HER2-positive and Signal... September 2, 2024 New obesity strategy is a ‘landmark day for the nation’s health’... July 27, 2020 Load more HOT NEWS High School Holds Early Graduation Ceremony For Teen With Terminal Cancer EMA Recommends Granting a Marketing Authorisation for Vorasidenib Fruquintinib Prolongs Survival Compared with Placebo in Heavily Pretreated Patients with... Adding Apalutamide to Perioperative ADT Associated with Better Outcomes of Radical...
